Safety and efficacy of Privigen®, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies

Journal of Clinical Immunology

Volumn 29, Issue 1, 2009, Pages 137-144

  Stein, Mark R ^a   Nelson, Robert P ^b   Church, Joseph A ^c   Wasserman, Richard L ^a   Borte, Michael ^d   Vermylen, Christiane ^e   Bichler, Johann ^a  

^a Indiana University Hospital ^*  (Switzerland)

^b INDIANA UNIVERSITY   (United States)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e CSL Behring AG   (Switzerland)

Author keywords

Common variable immunodeficiency (CVID); Intravenous immunoglobulin (IVIG); Primary immunodeficiency (PID); X linked agammaglobulinemia (XLA)

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; CORTICOSTEROID; DIPHENHYDRAMINE; IBUPROFEN; IMMUNOGLOBULIN G; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PRIVIGEN; UNCLASSIFIED DRUG;

ABSCESS; ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ARTICLE; BACKACHE; BACTEREMIA; BACTERIAL ARTHRITIS; BACTERIAL INFECTION; BACTERIAL MENINGITIS; CHILD; CHILL; CLINICAL TRIAL; COMMON VARIABLE IMMUNODEFICIENCY; COUGHING; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; INFUSION RATE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OSTEOMYELITIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRESCHOOL CHILD; PRIMARY IMMUNE DEFICIENCY; PRIORITY JOURNAL; SCHOOL CHILD; SEPTICEMIA; SINUSITIS; STOMACH DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; X LINKED AGAMMAGLOBULINEMIA;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 59549096424     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-008-9231-2     Document Type: Article

References (31)

1. OC Bruton 1952 Agammaglobulinemia Pediatrics 9 6 722 728
2. ER Stiehm JP Vaerman HH Fudenberg 1966 Plasma infusions in immunologic deficiency states: metabolic and therapeutic studies Blood 28 6 918 937
3. AJ Ammann RF Ashman RH Buckley WR Hardie HJ Krantmann J Nelson 1982 Use of intravenous gamma-globulin in antibody immunodeficiency: results of a multicenter controlled trial Clin Immunol Immunopathol 22 1 60 67
4. C Cunningham-Rundles FP Siegal EM Smithwick A Lion-Boule S Cunningham-Rundles J O'Malley 1984 Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease Ann Intern Med 101 4 435 439
5. RH Buckley RI Schiff 1991 The use of intravenous immune globulin in immunodeficiency diseases N Engl J Med 325 2 110 117
6. R Bolli MO Spycher R Brügger B Wüst K Gennari 1996 IgG-dimer formation in liquid immunoglobulin preparations is inhibited by nicotinamide and other amphiphilic compounds J Autoimmun 96 Suppl 1 96
7. TK Kumar D Samuel G Jayaraman T Srimathi C Yu 1998 The role of proline in the prevention of aggregation during protein folding in vitro Biochem Mol Biol Int 46 3 509 517
8. J Schnorf B Arnet A Burek-Kozlowska K Gennari R Rohner PJ Späth 1996
9. MD Kazatchkine SV Kaveri 2001 Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin N Engl J Med 345 10 747 755
10. W Druml G Heinzel G Kleinberger 2001 Amino acid kinetics in patients with sepsis Am J Clin Nutr 73 5 908 913
11. MO Spycher R Bolli G Hodler K Gennari A Hubsch P Späth 1996 Well-tolerated liquid intravenous immunoglobulin G preparations (IVIG) have a low immunoglobulin G dimer (IgG-dimer) content J Autoimmun 96 Suppl 1 96
12. C Kempf M Stucki N Boschetti 2007 Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins Biologicals 35 1 35 42
13. M Stucki N Boschetti W Schaefer T Hostettler F Kaesermann T Nowak 2008 Investigations of prion and virus safety of a new liquid IVIG product Biologicals 36 239 247
14. ME Conley LD Notarangelo A Etzioni 1999 Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies) Clin Immunol 93 3 190 197
15. FDA. Safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. Draft guidance for Industry. 2005.
16. Johnson NL, Kotz S. Discrete distributions. New York: Wiley; 1969.
17. Treatment experiences and preferences of patients with primary immune deficiency diseases. Survey results presented at the Immune Deficiency Foundation Meeting, 20 June 2003. 2003.
18. Golding B. IGIV clinical endpoints. Committee Update. In Proceedings of the 65th Meeting; 16 March 2000; Silver Spring, MD. 2000.
19. M Berger PJ Pinciaro 2004 Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases J Clin Immunol 24 4 389 396
20. JA Church H Leibl MR Stein IR Melamed A Rubinstein LC Schneider 2006 Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency J Clin Immunol 26 4 388 395
21. HD Ochs PJ Pinciaro 2004 Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases J Clin Immunol 24 3 309 314
22. CM Roifman H Schroeder M Berger R Sorensen M Ballow RH Buckley 2003 Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial Int Immunopharmacol 3 9 1325 1333
23. Work Loss Data Institute. Official disability guidelines. 2002;6/17(02). http://www.disabilitydurations.com/pr-repmdc.htm.
24. ER Stiehm 1997 Human intravenous immunoglobulin in primary and secondary antibody deficiencies Pediatr Infect Dis J 16 7 696 707
25. CM Roifman H Levison EW Gelfand 1987 High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease Lancet 1 8541 1075 1077
26. HD Ochs SH Fischer RJ Wedgwood DW Wara MJ Cowan AJ Ammann 1984 Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases Am J Med 76 3A 78 82
27. HW Eijkhout JW Der Meer CG Kallenberg RS Weening JT van Dissel LA Sanders 2001 The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial Ann Intern Med 135 3 165 174
28. Baxter Healthcare. Gammagard liquid summary basis of approval. Baxter Healthcare; 2004.
29. Flebogamma 5%, Prescribing Information. Grifols, December 2003.
30. VM Brennan NJ Salome-Bentley HM Chapel 2003 Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin Clin Exp Immunol 133 2 247 251
31. LR Pierce N Jain 2003 Risks associated with the use of intravenous immunoglobulin Transfus Med Rev 17 4 241 251